Edmond de Rothschild Holding’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $63.4M | Buy |
52,884
+10,007
| +23% | +$10.2M | 0.84% | 27 |
|
|
2026
Q1 | $39.4M | Sell |
42,877
-998
| -2% | -$1.01M | 0.57% | 54 |
|
|
2025
Q4 | $47.2M | Sell |
43,875
-9,275
| -17% | -$8.87M | 0.67% | 42 |
|
|
2025
Q3 | $40.6M | Sell |
53,150
-30
| -0.1% | -$22.3K | 0.63% | 41 |
|
|
2025
Q2 | $41.5M | Sell |
53,180
-8,728
| -14% | -$6.78M | 0.66% | 40 |
|
|
2025
Q1 | $51.1M | Sell |
61,908
-41,298
| -40% | -$34.4M | 0.9% | 24 |
|
|
2024
Q4 | $79.7M | Sell |
103,206
-751
| -0.7% | -$622K | 1.36% | 14 |
|
|
2024
Q3 | $92.1M | Buy |
103,957
+3,853
| +4% | +$3.46M | 1.48% | 12 |
|
|
2024
Q2 | $90.6M | Buy |
100,104
+43,717
| +78% | +$35M | 1.54% | 13 |
|
|
2024
Q1 | $43.9M | Buy |
56,387
+1,849
| +3% | +$1.32M | 0.73% | 35 |
|
|
2023
Q4 | $31.8M | Sell |
54,538
-28,290
| -34% | -$16.5M | 0.57% | 48 |
|
|
2023
Q3 | $44.5M | Buy |
82,828
+2,563
| +3% | +$1.32M | 0.9% | 29 |
|
|
2023
Q2 | $37.6M | Buy |
80,265
+15,770
| +24% | +$6.61M | 0.74% | 32 |
|
|
2023
Q1 | $22.1M | Sell |
64,495
-3,743
| -5% | -$1.26M | 0.5% | 55 |
|
|
2022
Q4 | $25M | Buy |
68,238
+4,275
| +7% | +$1.52M | 0.58% | 56 |
|
|
2022
Q3 | $20.7M | Sell |
63,963
-5,276
| -8% | -$1.67M | 0.55% | 54 |
|
|
2022
Q2 | $22.4M | Sell |
69,239
-17,111
| -20% | -$5.14M | 0.54% | 52 |
|
|
2022
Q1 | $24.7M | Sell |
86,350
-7,621
| -8% | -$1.96M | 0.54% | 56 |
|
|
2021
Q4 | $26M | Sell |
93,971
-15,740
| -14% | -$3.99M | 0.56% | 52 |
|
|
2021
Q3 | $25.3M | Sell |
109,711
-3,362
| -3% | -$830K | 0.59% | 51 |
|
|
2021
Q2 | $26M | Buy |
113,073
+600
| +0.5% | +$121K | 0.6% | 49 |
|
|
2021
Q1 | $21M | Sell |
112,473
-14,987
| -12% | -$2.93M | 0.58% | 53 |
|
|
2020
Q4 | $21.5M | Buy |
127,460
+97,460
| +325% | +$14.6M | 0.72% | 34 |
|
|
2020
Q3 | $4.44M | Buy |
+30,000
| New | +$4.64M | 0.18% | 133 |
|
|
2018
Q4 | – | Sell |
-2,000
| Closed | -$215K | – | 711 |
|
|
2018
Q3 | $215K | Hold |
2,000
| – | – | 0.01% | 435 |
|
|
2018
Q2 | $171K | Sell |
2,000
-5,000
| -71% | -$411K | ﹤0.01% | 498 |
|
|
2018
Q1 | $542K | Hold |
7,000
| – | – | 0.02% | 343 |
|
|
2017
Q4 | $591K | Hold |
7,000
| – | – | 0.02% | 336 |
|
|
2017
Q3 | $599K | Hold |
7,000
| – | – | 0.02% | 344 |
|
|
2017
Q2 | $576K | Sell |
7,000
-3,355
| -32% | -$274K | 0.02% | 352 |
|
|
2017
Q1 | $871K | Buy |
10,355
+4,980
| +93% | +$399K | 0.02% | 302 |
|
|
2016
Q4 | $395K | Sell |
5,375
-1,385
| -20% | -$103K | 0.01% | 403 |
|
|
2016
Q3 | $543K | Buy |
6,760
+540
| +9% | +$43.2K | 0.02% | 355 |
|
|
2016
Q2 | $490K | Sell |
6,220
-190
| -3% | -$14.3K | 0.02% | 373 |
|
|
2016
Q1 | $462K | Buy |
6,410
+910
| +17% | +$68.9K | 0.01% | 370 |
|
|
2015
Q4 | $463K | Buy |
5,500
+2,379
| +76% | +$197K | 0.01% | 373 |
|
|
2015
Q3 | $261K | Buy |
3,121
+540
| +21% | +$45.6K | 0.01% | 424 |
|
|
2015
Q2 | $215K | Buy |
+2,581
| New | +$197K | ﹤0.01% | 473 |
|
Other funds holding LLY
Edmond de Rothschild Holding's LLY Position: Q2 2026 in Review
Edmond de Rothschild Holding increased its Eli Lilly (LLY) stake by 23% in Q2 2026, buying an estimated $10.2M and bringing the position to 52,884 shares worth $63.4M. The position accounts for 0.84% of the portfolio, ranked #27.
Edmond de Rothschild Holding first reported a position in LLY in Q2 2015 and has held it in 38 quarters since. The position peaked at $92.1M in Q3 2024. 4,633 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Edmond de Rothschild Holding held 52,884 shares of Eli Lilly worth $63.4M as of Q2 2026.
- Edmond de Rothschild Holding bought 10,007 Eli Lilly shares in Q2 2026, an estimated $10.2M.
- Eli Lilly made up 0.84% of Edmond de Rothschild Holding's portfolio in Q2 2026, its #27 holding.
- Edmond de Rothschild Holding first reported a position in Eli Lilly in Q2 2015 and has held it in 38 quarters since.
- Edmond de Rothschild Holding's Eli Lilly position peaked at $92.1M in Q3 2024.
- 4,633 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Edmond de Rothschild Holding's 13F filing for Q2 2026, filed 10 Aug 2026.